Complete Clinical Response After Neoadjuvant Chemoradiotherapy for Squamous Cell Cancer of the Thoracic Oesophagus: Is Surgery Always Necessary?
Carlo Castoro(Humanitas University), Ermanno Ancona(University of Padua), Alberto Ruol(University of Padua), Marco Scarpa(University of Padua), Silvia Michieletto(Istituto Oncologico Veneto), L. Corti(Istituto Oncologico Veneto), Francesco Cavallin, Rita Alfieri(Istituto Oncologico Veneto), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Giampietro Zanchettin(University of Padua), Matteo Cagol(Istituto Oncologico Veneto)
Cited by 95
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k